Paraoxonase status in coronary heart disease: Are activity and concentration more important than genotype?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 9, 2001, Pages 1451-1457

  Mackness, Bharti ^a,c   Davies, Gershan K ^b   Turkie, Wajdi ^a   Lee, Evelyn ^b   Roberts, David H ^b   Hill, Elizabeth ^a   Roberts, Chris ^a   Durrington, Paul N ^a   Mackness, Michael I ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b BLACKPOOL VICTORIA HOSPITAL   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Coronary heart disease; Genetic polymorphisms; Oxidation; Paraoxonase

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; CLUSTERIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARAOXON;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CASE CONTROL STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL;

EID: 0035574446     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/hq0901.094247     Document Type: Article

References (65)

1. Serum esterase I: Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate and a method for their determination
2. Serum esterase II: An enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera
3. Human serum paraoxonase/arylesterase
4. Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins
5. Antioxidative effect of high density lipoproteins in the oxidation of low density lipoproteins
6. The role of high density lipoprotein and lipid soluble antioxidant vitamins in inhibiting low density lipoprotein oxidation
7. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein
8. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein
9. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity
10. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation
11. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein
12. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase
13. Protective effect of high density lipoprotein associated paraoxonase: Inhibition of the biological activity of minimally oxidised low-density lipoprotein
14. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus
15. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins
16. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes
17. The molecular basis of the human serum paraoxonase activity polymorphism
18. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin
19. Paraoxonase polymorphism Met-Leu54 is associated with modified concentrations of the enzyme
20. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon
21. The alloenzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low density lipoprotein against lipid-peroxidation
22. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification
23. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective active of human paraoxonase alloenzymes Q and R
24. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes
25. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease
26. 192-Arg) is associated with coronary heart disease in Japanese non-insulin-dependent diabetes mellitus
27. A 192-Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese
28. Paraoxonase 192 Glu/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes
29. Paraoxonase gene polymorphism and coronary artery disease in Indian subjects
30. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases
31. Genetic polymorphism of paraoxonase and the risk of coronary heart disease
32. The Gln-Arg 191 polymorphism of human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns
33. Risk of myocardial infarction with Gln/Arg 192 polymorphisms in the human paraoxonase gene and diabetes mellitus
34. Mutations in the human paraoxonase 1 gene: Frequencies, allelic linkages and association with coronary artery disease
35. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study
36. The Gln-Arg 192 polymorphism of the human paraoxonase gene is not associated with coronary artery disease in Italian patients
37. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease
38. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease
39. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan
40. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients
41. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response
42. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio
43. Serum paraoxonase after myocardial infarction
44. Meta-analysis in clinical trials
45. Bias in meta-analysis detected by a simple graphical test
46. Summing up evidence: One answer is not always enough
47. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus
48. How high-density lipoprotein protects against the effects of lipid peroxidation
49. Quantification of human serum paraoxonase by enzyme-linked immunoassay: Population differences in protein concentrations
50. Paraoxonase activity in two healthy populations with differing rates of coronary heart disease
51. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model
52. Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits
53. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat
54. Oxidative status of lipoproteins in coronary disease patients
55. Human serum paraoxonase (PON1) is inactivated by oxidised low density lipoprotein and preserved by antioxidants
56. Promoter polymorphisms of the human paraoxonase PON1 gene and serum activities and concentrations
57. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients
58. 55 genotype
59. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
60. Lack of protection against oxidative modification of LDL by avian HDL
61. Does paraoxonase play a role in susceptibility to cardiovascular disease?
62. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Step 1
63. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3
64. Determination of paraoxonase (PON1) status requires more than genotyping